Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions*

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Critical Care Medicine

• Publication date

  2009-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CCM.0b013e318192843bPMID 19050637
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).

  2007cited by this paper
• Is industry guiding the sepsis guidelines? A perspective

  2007cited by this paper
• Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey

  2007cited by this paper
• Recombinant human activated protein C sentenced to the death of a thousand cuts?

  2007cited by this paper
• Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study

  2007cited by this paper
• An Opinion Too Far—The Campaign Against the Surviving Sepsis Campaign

  2006cited by this paper
• Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

  2005cited by this paper
• Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

  2005cited by this paper
• Substantiating the concerns about recombinant human activated protein C use in sepsis*

  2004cited by this paper
• Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials

  2003cited by this paper
• Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis

  2003cited by this paper
• Efficacy and safety of recombinant human activated protein C for severe sepsis.

  2001cited by this paper

• Innovation in Enrichment: Is Persistence Enough?

  2024cites this paper
• Structure-guided protein engineering of human cathepsin L for efficient collagenolytic activity.

  2021cites this paper
• Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

  2020cites this paper
• The contact pathway and sepsis

  2019cites this paper
• Catheter‐directed Thrombolysis for Intermediate‐Risk Pulmonary Embolism

  2017cites this paper
• Emerging technologies for protease engineering: New tools to clear out disease.

  2017cites this paper
• Microcirculatory dysfunction in sepsis: pathophysiology, clinical monitoring, and potential therapies.

  2016cites this paper
• Annexin A5 Increases Survival in Murine Sepsis Model by Inhibiting HMGB1-Mediated Proinflammation and Coagulation

  2016cites this paper
• What is the role of recombinant activated protein C in the management of sepsis?

  2016cites this paper
• Small Vessels-Big Problems : Novel Insights into Microvascular Mechanisms of Diseases Microcirculatory dysfunction in sepsis : pathophysiology , clinical monitoring , and potential therapies

  2016cites this paper
• Pharmacotherapy of Sepsis

  2015cites this paper
• Recombinant Human Annexin A5 Inhibits Proinflammatory Response and Improves Cardiac Function and Survival in Mice With Endotoxemia*

  2014cites this paper
• Classification tree analysis of the factors influencing injury-related disability caused by the Wenchuan earthquake

  2014cites this paper
• Vascular Immunotargeting to Endothelial Determinant ICAM-1 Enables Optimal Partnering of Recombinant scFv-Thrombomodulin Fusion with Endogenous Cofactor

  2013cites this paper
• Protein C and acute inflammation: a clinical and biological perspective.

  2013cites this paper
• Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center

  2013influential citation
• Why Activated Protein C Was Not Successful in Severe Sepsis and Septic Shock: Are We Still Tilting at Windmills?

  2013cites this paper
• Adverse events and clinical outcome associated with drotrecogin alfa-activated: a single-center experience of 498 patients over 8 years.

  2012cites this paper
• A multicenter evaluation of the safety of drotrecogin alfa (activated) in patients with baseline bleeding precautions.

  2012cites this paper
• Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.

  2012cites this paper
• Recombinant human activated protein C for severe sepsis in neonates.

  2012cites this paper
• Kapitel 6 – Therapie von schweren Infektionen

  2011cites this paper
• Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study

  2011cites this paper
• Readministration of drotrecogin alfa (activated) in an adult with severe sepsis.

  2011cites this paper
• The individual and unique roles for eosinophils and interleukin-5 in the innate immune response to sepsis

  2011cites this paper
• The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis

  2011cites this paper
• Proteases as therapeutics.

  2011cites this paper
• Immature platelet fraction as predictive index of sepsis

  2010cites this paper
• An update on activated protein C (xigris) in the management of sepsis.

  2010cites this paper
• Prevalence of Serious Bleeding Events and Intracranial Hemorrhage in Patients Receiving Activated Protein C: A Systematic Review and Meta-analysis

  2010cites this paper
• Update on the role of Toll-like receptors during bacterial infections and sepsis

  2010cites this paper
• Which protein C after cardiac surgery?

  2010cites this paper
• Adverse drug events associated with disorders of coagulation

  2010influential citation
• Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions

  2010cites this paper
• Case Report: Perioperative Use of Protein C Concentrate for Protein C Deficiency in THA

  2010cites this paper
• Argatroban for anticoagulation in continuous renal replacement therapy.

  2009cites this paper
• Chapter 33 - Blood, blood components, plasma, and plasma products

  2009cites this paper
• Recombinant human activated protein C, package labeling, and hemorrhage risks.

  2009cites this paper
• Human plasma kallikrein-kinin system: physiological and biochemical parameters.

  2009cites this paper
• Drotrecogin Alfa: Safety Review

  2009cites this paper
• Recombinant activated protein C and risk of bleeding.

  2009cites this paper
• When less is more in the intensive care unit; lessons learned.

  2009cites this paper
• Recombinant activated protein C and risk of bleeding.

  2009cites this paper
• O R I G I N a L C L I N I C a L I N V E S T I G a T I O N Open Access

  year unknowncites this paper
• Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Growing Insights into the Potential Benefits and Risks of Activated Protein C Administration in Sepsis: a Review of Preclinical and Clinical Studies

  year unknowncites this paper